Sfoglia per Autore
Ticlopidine’s safety profile: a case/non case study on the basis of the spontaneous ADR reporting in Italy.
2009 Motola D.; Roberto G.; Biagi C.; Vargiu A.; Donati M.; Costantini D.; Montanaro N.
Progressive Multifocal Leukoencephalopathy: an effect of immunodeficiency or an adverse drug reaction?
2009 Piccinni C.; Sacripanti C.; Poluzzi E.; Motola D.; Magro L.; Moretti U.; Conforti A.; Montanaro N.
La rimborsabilità di memantina - il trilemma di Münchausen
2009 N. Montanaro; C. Piccinni; P. Carta; L. Bozzini
Progressive Multifocal Leukoencephalopathy (PML): only immunosuppressive complication or also drug adverse reaction?
2009 Piccinni C.; Sacripanti C.; Poluzzi E.; Motola D.; Magro L.; Moretti U.; Montanaro N.
Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy
2010 Lapi F.; Tuccori M.; Motola D.; Pugi A.; Vietri M.; Montanaro N.; Vaccheri A.; Leoni O.; Cocci A.; Leone R.; Conforti A.; Moretti U.; Sessa E.; Mazzaglia G.; Mugelli A.; Mazzei T.; Vannacci A.
Cardiovascular events in statin recipients: a 3-year record-linkage study on prescription and hospital discharge databases
2010 Poluzzi E.; Piccinni C.; Carta P.; Puccini A.; Lanzoni M.; Motola D.; Vaccheri A. ; De Ponti F.; Montanaro N.
Safety profile of thiazolidinediones on the basis of the FDA-AERS database: cardiovascular and bone fracture risks for rosiglitazone and pioglitazone
2010 Motola D.; Poluzzi E.; Marra A.; Biagi C.; Piccinni C.; Montanaro N.
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
2010 Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N.
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.
2010 Chiabrando G; Bianchi S; Poluzzi E; Montanaro N; Scanavacca P.
Pattern of Triptan Use in a Sample of the Italian General Population
2010 C. Biagi; E. Poluzzi; D. Motola; G. Roberto; A. Puccini; A. Vaccheri; R. D’Alessandro; N. Montanaro.
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study
2011 Poluzzi E.; Piccinni C.; Carta P.; Puccini A.; Lanzoni M.; Motola D.; Vaccheri A.; De Ponti F.; Montanaro N.
Three years of experience: the Italian registry and safety data update
2011 G.L. Mancardi; G. Tedeschi; M.P. Amato; R. D’Alessandro; F. Drago; C. Milanese; P. Popoli; P. Rossi; G. Savettieri; M.R. Tola; G. Comi; C. Pozzilli; A. Bertolotto; M.G. Marrosu; L.M.E. Grimaldi; A. Laroni; N. Vanacore; A. Covezzoli; M. De Rosa; C. Piccinni; N. Montanaro; L. Periotto; R. Iommelli; C. Tomino; L. Provinciali
Analyses of natalizumab prescriptions and discontinuations in multiple sclerosis patients of an Italian region
2011 Sacripanti C; Piccinni C; Puccini A; Poluzzi E; Montanaro N
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy
2011 Biagi C.; Poluzzi E.; Roberto G.; Puccini A.; Vaccheri A.; D'Alessandro R.; Motola D.; Montanaro N.
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to Bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures,
2011 Lapi F.; Sessa E.; Di Bari M.; Corrao G.; Zambon A.; Scotti L.; Sturkenboom M.; Geppetti .P; Gregori D.; Carle F.; Menna A.; Vestri A.R.; Vaccheri A.; Piccinni C.; Puccini A.; Montanaro N.; Arcoraci V.; Caputi A.P.; Mazzaglia G.
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures
2011 Lapi F.; Sessa E.; Di Bari M.; Corrao G.; Zambon A.; Scotti L.; Sturkenboom M.; Geppetti P.; Gregori D.; Carle F.; Menna A.; Vestri A.R.; Vaccheri A.; Piccinni C.; Puccini A.; Montanaro N.; Caputi A.P.; Mazzaglia G.
Risk-management of natalizumab: a drug utilization study on duration of therapy and cause of discontinuation in Emilia-Romagna region
2011 Sacripanti C.; Piccinni C.; Puccini A.; Poluzzi E.; Montanaro N.
Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy
2012 D. Motola; C. Biagi; R. Leone; M. Venegoni; F. Lapi; P. Cutroneo; A. Vargiu; R. Bonaiuti; N. Montanaro; A. Vaccheri
Triptans and serious cardiovascular events: possible safety signals from the FDA Adverse Event Reporting System database
2012 Roberto G; Piccinni C; Biagi C; Koci A; Motola D; Vaccheri A; Montanaro N; Poluzzi E.
Un commento alla lettera sulla definizione di farmaco innovativo
2012 Motola D.; Montanaro N.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Ticlopidine’s safety profile: a case/non case study on the basis of the spontaneous ADR reporting in Italy. | Motola D.; Roberto G.; Biagi C.; Vargiu A.; Donati M.; Costantini D.; Montanaro N. | 2009-01-01 | BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | - | 4.02 Riassunto (Abstract) | - |
Progressive Multifocal Leukoencephalopathy: an effect of immunodeficiency or an adverse drug reaction? | Piccinni C.; Sacripanti C.; Poluzzi E.; Motola D.; Magro L.; Moretti U.; Conforti A.; Montanaro N. | 2009-01-01 | - | Società Italiana di Farmacologia | 4.02 Riassunto (Abstract) | - |
La rimborsabilità di memantina - il trilemma di Münchausen | N. Montanaro; C. Piccinni; P. Carta; L. Bozzini | 2009-01-01 | DIALOGO SUI FARMACI | - | 1.01 Articolo in rivista | - |
Progressive Multifocal Leukoencephalopathy (PML): only immunosuppressive complication or also drug adverse reaction? | Piccinni C.; Sacripanti C.; Poluzzi E.; Motola D.; Magro L.; Moretti U.; Montanaro N. | 2009-01-01 | BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | Wiley B | 4.02 Riassunto (Abstract) | - |
Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy | Lapi F.; Tuccori M.; Motola D.; Pugi A.; Vietri M.; Montanaro N.; Vaccheri A.; Leoni O.; Cocci A....; Leone R.; Conforti A.; Moretti U.; Sessa E.; Mazzaglia G.; Mugelli A.; Mazzei T.; Vannacci A. | 2010-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | - |
Cardiovascular events in statin recipients: a 3-year record-linkage study on prescription and hospital discharge databases | Poluzzi E.; Piccinni C.; Carta P.; Puccini A.; Lanzoni M.; Motola D.; Vaccheri A. ; De Ponti F.; ...Montanaro N. | 2010-01-01 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | Wiley Blackewell | 4.02 Riassunto (Abstract) | - |
Safety profile of thiazolidinediones on the basis of the FDA-AERS database: cardiovascular and bone fracture risks for rosiglitazone and pioglitazone | Motola D.; Poluzzi E.; Marra A.; Biagi C.; Piccinni C.; Montanaro N. | 2010-01-01 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | Wiley Blackewell | 4.02 Riassunto (Abstract) | - |
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. | Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N. | 2010-01-01 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. | Chiabrando G; Bianchi S; Poluzzi E; Montanaro N; Scanavacca P. | 2010-01-01 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
Pattern of Triptan Use in a Sample of the Italian General Population | C. Biagi; E. Poluzzi; D. Motola; G. Roberto; A. Puccini; A. Vaccheri; R. D’Alessandro; N. Montanaro. | 2010-01-01 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | - | 4.02 Riassunto (Abstract) | - |
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study | Poluzzi E.; Piccinni C.; Carta P.; Puccini A.; Lanzoni M.; Motola D.; Vaccheri A.; De Ponti F.; M...ontanaro N. | 2011-01-01 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
Three years of experience: the Italian registry and safety data update | G.L. Mancardi; G. Tedeschi; M.P. Amato; R. D’Alessandro; F. Drago; C. Milanese; P. Popoli; P. Ros...si; G. Savettieri; M.R. Tola; G. Comi; C. Pozzilli; A. Bertolotto; M.G. Marrosu; L.M.E. Grimaldi; A. Laroni; N. Vanacore; A. Covezzoli; M. De Rosa; C. Piccinni; N. Montanaro; L. Periotto; R. Iommelli; C. Tomino; L. Provinciali | 2011-01-01 | NEUROLOGICAL SCIENCES | - | 1.01 Articolo in rivista | - |
Analyses of natalizumab prescriptions and discontinuations in multiple sclerosis patients of an Italian region | Sacripanti C; Piccinni C; Puccini A; Poluzzi E; Montanaro N | 2011-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy | Biagi C.; Poluzzi E.; Roberto G.; Puccini A.; Vaccheri A.; D'Alessandro R.; Motola D.; Montanaro N. | 2011-01-01 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to Bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures, | Lapi F.; Sessa E.; Di Bari M.; Corrao G.; Zambon A.; Scotti L.; Sturkenboom M.; Geppetti .P; Greg...ori D.; Carle F.; Menna A.; Vestri A.R.; Vaccheri A.; Piccinni C.; Puccini A.; Montanaro N.; Arcoraci V.; Caputi A.P.; Mazzaglia G. | 2011-01-01 | - | Società Italiana di Farmacologia | 4.02 Riassunto (Abstract) | - |
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures | Lapi F.; Sessa E.; Di Bari M.; Corrao G.; Zambon A.; Scotti L.; Sturkenboom M.; Geppetti P.; Greg...ori D.; Carle F.; Menna A.; Vestri A.R.; Vaccheri A.; Piccinni C.; Puccini A.; Montanaro N.; Caputi A.P.; Mazzaglia G. | 2011-01-01 | BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | Wiley Blackewell | 4.02 Riassunto (Abstract) | - |
Risk-management of natalizumab: a drug utilization study on duration of therapy and cause of discontinuation in Emilia-Romagna region | Sacripanti C.; Piccinni C.; Puccini A.; Poluzzi E.; Montanaro N. | 2011-01-01 | - | Società Italiana di Farmacologia | 4.02 Riassunto (Abstract) | - |
Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy |
D. Motola; C. Biagi; R. Leone; M. Venegoni; F. Lapi; P. Cutroneo; A. Vargiu; R. Bonaiuti; N. Mont...anaro; A. Vaccheri |
2012-01-01 | CURRENT DRUG SAFETY | - | 1.01 Articolo in rivista | - |
Triptans and serious cardiovascular events: possible safety signals from the FDA Adverse Event Reporting System database | Roberto G; Piccinni C; Biagi C; Koci A; Motola D; Vaccheri A; Montanaro N; Poluzzi E. | 2012-01-01 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | Wiley Blackewell | 4.02 Riassunto (Abstract) | - |
Un commento alla lettera sulla definizione di farmaco innovativo | Motola D.; Montanaro N. | 2012-01-01 | PHARMACOECONOMICS, ITALIAN RESEARCH ARTICLES | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile